UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2018

Commission File Number: 001-37993

OBSEVA SA
(Translation of registrant's name into English)

Chemin des Aulx, 12
1228 Plan-les-Ouates
Geneva, Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (No. 333-222820 and 333-221462) of ObsEva SA (including any prospectuses forming a part of such registration statements) and the registration statement on Form S-8 (Registration Number 333-216170) of ObsEva SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit 99.3 to this Report on Form 6-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

RISK FACTORS

The risk factors set forth in the discussion of material risks in Item 3.D of our Annual Report on Form 20-F for the fiscal year ended December 31, 2017 are incorporated herein. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, also may affect our business, financial condition and/or future operating results.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Unaudited Consolidated Interim Financial Statements
99.2	Management's Discussion and Analysis of Financial Condition and Results of Operations
99.3	Press Release dated May 16, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ObsEva SA

Date: May 16, 2018

By: /s/ Ernest Loumaye
Name Ernest Loumaye
Title: Chief Executive Officer

Exhibit 99.1

OBSEVA SA

INDEX TO UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

ObsEva SA

Consolidated Interim Financial Statements

Consolidated Balance Sheets

(in USD '000)	Notes	March 31, 2018	December 31, 2017
		unaudited	*audited*
ASSETS			
Current assets			
Cash and cash equivalents	4	95,435	110,841
Other receivables		791	783
Prepaid expenses		1,786	1,490
Total current assets		**98,012**	**113,114**
Non-current assets			
Furniture, fixtures and equipment		310	323
Intangible assets	5	21,608	21,608
Other long-term assets		192	190
Total non-current assets		**22,110**	**22,121**
Total assets		**120,122**	**135,235**
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			
Current tax liability		27	51
Other payables and current liabilities		1,613	2,865
Accrued expenses		10,106	6,514
Total current liabilities		**11,746**	**9,430**
Non-current liabilities			
Post-employment obligations		3,063	3,099
Other long-term liabilities		53	55
Total non-current liabilities		**3,116**	**3,154**
Shareholders' equity			
Share capital		2,871	2,864
Share premium		220,141	219,335
Reserves		8,721	7,119
Accumulated losses		(126,473)	(106,667)
Total shareholders' equity	6	**105,260**	**122,651**
Total liabilities and shareholders' equity		**120,122**	**135,235**

The accompanying notes form an integral part of these consolidated interim financial statements.

ObsEva SA

Consolidated Interim Financial Statements

Consolidated Statements of Comprehensive Loss

(in USD '000, except per share data)	Notes	Three-month period ended March 31, 2018	2017
		unaudited	
Operating income other than revenue		**5**	**6**
OPERATING EXPENSES			
Research and development expenses	7	(16,342)	(13,057)
General and administrative expenses		(3,649)	(2,745)
Total operating expenses		**(19,991)**	**(15,802)**
OPERATING LOSS		**(19,986)**	**(15,796)**
Finance income		155	258
Finance expense		—	—
NET LOSS BEFORE TAX		**(19,831)**	**(15,538)**
Income tax benefit	8	25	—
NET LOSS FOR THE PERIOD		**(19,806)**	**(15,538)**
Net loss per share			
Basic	9	(0.54)	(0.58)
Diluted	9	(0.54)	(0.58)
OTHER COMPREHENSIVE LOSS			
Items that will not be reclassified to profit and loss			
Remeasurements on post-employment benefit plans		—	—
Items that may be reclassified to profit or loss			
Currency translation differences		—	—
TOTAL OTHER COMPREHENSIVE LOSS		**—**	**—**
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD		**(19,806)**	**(15,538)**

The accompanying notes form an integral part of these consolidated interim financial statements.

ObsEva SA

Consolidated Interim Financial Statements

Consolidated Statement of Cash Flows

(in USD '000)	Notes	Three-month period ended March 31, 2018	2017
		unaudited	
NET LOSS BEFORE TAX FOR THE PERIOD		**(19,831)**	**(15,538)**
Adjustments for:			
Depreciation		26	12
Post-employment benefit		(36)	27
Share-based payments		2,421	2,324
Finance income		(155)	(258)
Increase in other receivables		(8)	(205)
(Increase) / decrease in prepaid expenses and other long term-assets		(298)	1,081
Decrease in other payables and current liabilities		(1,169)	(547)
Increase in accrued expenses and other long-term liabilities		4,288	2,513
NET CASH FLOWS USED IN OPERATING ACTIVITIES		**(14,762)**	**(10,591)**
Payments for plant and equipment		(96)	(9)
NET CASH FLOWS USED IN INVESTING ACTIVITIES		**(96)**	**(9)**
Proceeds from issue of shares		8	96,754
Payment of share issuance costs		(710)	(7,769)
Interest received		—	—
Interest paid		—	—
NET CASH FLOWS (USED IN) / FROM FINANCING ACTIVITIES		**(702)**	**88,985**
Net (decrease) / increase in cash and cash equivalents		(15,560)	78,385
Cash and cash equivalents as at January 1,		**110,841**	**25,508**
Effects of exchange rate changes on cash and cash equivalents		154	265
Cash and cash equivalents as at March 31,		**95,435**	**104,158**

The accompanying notes form an integral part of these consolidated interim financial statements.

ObsEva SA

Consolidated Interim Financial Statements

Consolidated Statement of Changes in Equity

(in USD '000) *unaudited*	Share capital	Share premium	Share-based payments reserve	Foreign currency translation reserve	Total reserves	Accumulated losses	Total
January 1, 2017	**1,740**	**71,966**	**2,423**	**(489)**	**1,934**	**(39,599)**	**36,041**
Loss for the period	—	—	—	—	—	(15,538)	(15,538)
Other comprehensive loss	—	—	—	—	—	—	—
Total comprehensive loss	**—**	**—**	**—**	**—**	**—**	**(15,538)**	**(15,538)**
Issuance of shares - IPO	496	96,254	—	—	—	—	96,750
Issuance of shares - Incentive Plan	4	138	(138)	—	(138)	—	4
Share issuance costs	—	(8,098)	—	—	—	—	(8,098)
Share-based remuneration	—	—	2,324	—	2,324	—	2,324
March 31, 2017	**2,240**	**160,260**	**4,609**	**(489)**	**4,120**	**(55,137)**	**111,483**
January 1, 2018	**2,864**	**219,335**	**7,608**	**(489)**	**7,119**	**(106,667)**	**122,651**
Loss for the period	—	—	—	—	—	(19,806)	(19,806)
Other comprehensive loss	—	—	—	—	—	—	—
Total comprehensive loss	**—**	**—**	**—**	**—**	**—**	**(19,806)**	**(19,806)**
Issuance of shares - Incentive Plan	7	819	(819)	—	(819)	—	7
Share issuance costs	—	(13)	—	—	—	—	(13)
Share-based remuneration	—	—	2,421	—	2,421	—	2,421
March 31, 2018	**2,871**	**220,141**	**9,210**	**(489)**	**8,721**	**(126,473)**	**105,260**

The accompanying notes form an integral part of these consolidated interim financial statements.

1. General information

ObsEva SA (the "Company") was founded on November 14, 2012, and its address is 12 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland. The terms "ObsEva" or "the Group" refer to ObsEva SA together with its subsidiaries included in the scope of consolidation (note 2.3).

The Group is focused on the development and commercialization of novel therapeutics for serious conditions that compromise women's reproductive health and pregnancy. The Group has a portfolio of three mid- to late-stage development in-licensed compounds (OBE2109, OBE001 ("nolasiban") and OBE022) being developed in four indications. The Group has no currently marketed products.

These consolidated interim financial statements are presented in dollars of the United States (USD), rounded to the nearest thousand except share and per share data, and have been prepared on the basis of the accounting principles described in note 2.

These consolidated interim financial statements were authorized for issue by the Audit Committee of the Company's Board of Directors (the "Board of Directors") on May 14, 2018.

2. Accounting principles and scope of consolidation

2.1 Basis of preparation and accounting principles

These unaudited three-month consolidated interim financial statements (the "interim financial statements") are prepared in accordance with International Accounting Standard ("IAS") 34 *Interim Financial Reporting* as issued by the International Accounting Standards Board (the "IASB").

On January 1, 2018, the Group adopted IFRS 9 *Financial Instruments*, which replaced IAS 39 *Financial Instruments: Recognition and Measurement*. The adoption of the standard had no impact on the Group's consolidated financial statements.

Other accounting policies used in the preparation and presentation of these consolidated interim financial statements are consistent with those used in the consolidated financial statements for the year ended December 31, 2017 (the "annual financial statements"), which should be read in conjunction with these consolidated interim financial statements as they provide an update of previously reported information.

The Group believes it will be able to meet all of its obligations as they fall due for at least 12 months from March 31, 2018, hence, the unaudited consolidated interim financial statements have been prepared on a going concern basis.

2.2 Use of estimates and assumptions

The preparation of consolidated interim financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the interim financial statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the consolidated interim financial statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate during the period in which the circumstances change.

2.3 Scope of consolidation

There was no change to the scope of consolidation during the reporting period and the Company consolidates the financial operations of its two fully-owned subsidiaries, ObsEva Ireland Ltd, which is registered in Cork, Ireland and organized under the laws of Ireland, and ObsEva USA Inc., which is registered and organized under the laws of Delaware, USA. ObsEva Ireland Ltd had no operations and no results of operations to report as of March 31, 2018 and 2017.

3. Fair value estimation and financial instruments

The carrying value less impairment provision of receivables and payables approximate their fair values due to their short-term nature.

All financial assets and liabilities, respectively, are held at their amortized cost.

The Group's financial assets and liabilities consist of cash and cash equivalents, other receivables, other payables and accruals which are classified as loans and receivables at amortized costs according to IFRS 9.

4. Cash and cash equivalents

(in USD '000)	March 31, 2018	December 31, 2017
	unaudited	*audited*
Bank deposits	95,435	110,841
Interest bearing deposits	—	—
Total cash and cash equivalents	**95,435**	**110,841**

5. Intangible assets

As at March 31, 2018 and December 31, 2017, the Group holds a number of licenses to develop and commercialize several biopharmaceutical product candidates, the value of which is recorded at USD 21.6 million.

6. Shareholders' equity

On January 30, 2017, the Company completed an IPO and issued 6,450,000 common shares at a subscription price of USD 15.00 per share and a par value of 1/13 of a Swiss franc per share. The gross proceeds of USD 96.8 million have been recorded in equity net of directly related share issuance costs of USD 8.2 million.

On October 13, 2017, the Company completed a private placement with institutional investors and issued 7,500,000 common shares at a subscription price of USD 8.00 per share and a par value of 1/13 of a Swiss franc per share. The gross proceeds of USD 60.0 million have been recorded in equity net of directly related share issuance costs of USD 3.7 million.

On March 16, 2018, the Company issued 3,499,990 common shares at par value of 1/13 of a Swiss franc per share. The shares were subscribed by the Company and are held as treasury shares, hence the operation did not impact the share capital. Share issuance costs of USD 11 thousand related to the operation were recorded in equity.

As at March 31, 2018, the total outstanding share capital of USD 2.9 million, fully paid, consists of 36,436,211 common shares, excluding 684,868 non-vested shares and 3,510,173 treasury shares. As at December 31, 2017, the total outstanding share capital of USD 2.9 million, fully paid, consists of 36,342,945 common shares, excluding 778,134 non-vested shares and 10,183 treasury shares. All shares have a nominal value of 1/13 of a Swiss franc, translated into USD using historical rates at the issuance date.

7. Research and development expenses

Due to the difficulty in assessing when research and development projects would generate revenue, the Group expenses all research and development costs to the profit and loss accounts.

8. Income tax

The Group is subject to income taxes in Switzerland, Ireland and the United States.

The Company is subject in Switzerland to a municipal and cantonal income tax rate of 22.6% and to a federal tax rate of 8.5% on its profits after tax. It is entitled to carry forward any loss incurred for a period of seven years and can offset such losses carried forward against future taxes. In 2015, the Company was granted by the State Council of the Canton of Geneva an exemption of income and capital tax at municipal and cantonal levels for the period from 2013 until 2022. Because of this exemption, and the fact that the Company has incurred net losses since its inception, no income tax expense at the municipal, cantonal or federal levels was recorded in the Company for the three-month periods ended March 31, 2018 and 2017. Additionally, due to the uncertainty as to whether it will

be able to use its net loss carryforwards for tax purposes in the future, no deferred taxes have been recognized on the balance sheet of the Company as of March 31, 2018 and December 31, 2017.

The Company's Irish subsidiary has no activity, and, therefore, no income tax expense was recorded in such entity for the three-month periods ended March 31, 2018 and 2017.

The Company's U.S. subsidiary is a service organization for the Group and will therefore be subject to taxes on the revenues generated from its services to the Group that are charged based upon the U.S. subsidiary's cost plus arrangement with the Group. The profits of the U.S. subsidiary during the three-month periods ended March 31, 2018 and 2017 were subject to a total U.S. income tax rate of 27.3% and 39.3%, respectively, based on both the U.S. federal and Massachusetts state tax rates.

9. Loss per share

As of March 31, 2018 and 2017, the Company has one category of shares, which are common shares. The basic loss per share is calculated by dividing the loss of the period attributable to the common shares by the weighted average number of common shares outstanding during the period as follows:

	Three-month period ended March 31, 2018 *unaudited*
	Common shares
Net loss attributable to shareholders (in USD '000)	(19,806)
Weighted average number of shares outstanding	36,389,578
Basic and diluted loss per share (in USD)	**(0.54)**

	Three-month period ended March 31, 2017 *unaudited*
	Common shares
Net loss attributable to shareholders (in USD '000)	(15,538)
Weighted average number of shares outstanding	26,623,553
Basic and diluted loss per share (in USD)	**(0.58)**

For the three-month period ended March 31, 2018, 684,868 non-vested shares, 3,510,173 treasury shares and 1,881,740 shares issuable upon the exercise of stock-options, which would have an anti-dilutive impact on the calculation of the diluted earnings per share, were excluded from the calculation. For the three-month period ended March 31, 2017, 1,184,023 non-vested shares, 5,200 treasury shares and 428,450 shares issuable upon the exercise of stock-options, which would have an anti-dilutive impact on the calculation of the diluted earnings per share, are excluded from the calculation.

10. Segment information

The Group operates in one segment, which is the research and development of innovative women's reproductive, health and pregnancy therapeutics. The marketing and commercialization of such therapeutics depend, in large part, on the success of the development phase. The Chief Executive Officer of the Company reviews the consolidated statement of operations of the Group on an aggregated basis and manages the operations of the Group as a single operating segment. The Group currently generates no revenue from the sales of therapeutics products, and the Group's activities are not affected by any significant seasonal effect.

The geographical analysis of non-current assets is as follows:

(in USD '000)	**March 31, 2018** *unaudited*	**December 31, 2017** *audited*
Switzerland	21,829	21,832
USA	281	289
Total non-current assets	**22,110**	**22,121**

The geographical analysis of operating expenses is as follows:

unaudited **(in USD '000)**	**Three-month period ended March 31,**	
	2018	**2017**
Switzerland	19,018	15,232
USA	973	570
Total operating expenses	**19,991**	**15,802**

11. Events after the reporting period

There were no material events after the balance sheet date.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. We are focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions that affect their quality of life, ability to conceive or that complicate pregnancy and the health of newborns. Our goal is to build the leading women's reproductive health and pregnancy company focused on these conditions where current treatment options are limited and significant unmet needs exist.

We are developing OBE2109 as a novel, oral gonadotropin releasing hormone, or GnRH, receptor antagonist, for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We are currently conducting a multiple-dose, placebo-controlled Phase 2b clinical trial of OBE2109 in approximately 330 patients with endometriosis, or the EDELWEISS clinical trial. Patient recruitment was completed in November 2017, and we expect to report the primary efficacy results from the first 12-week evaluation period of this trial by the end of the second quarter of 2018. We expect to receive 24-week treatment data, including bone mineral density safety assessments, in the fourth quarter of 2018. Assuming the results of the trial are favorable, we plan to request an end-of-Phase 2 meeting with the FDA by the end of 2018. For the uterine fibroids indication, in April 2017, we initiated a Phase 3 clinical development program with two Phase 3 clinical trials, or the PRIMROSE 1 and 2 clinical trials. We expect to complete patient enrollment in these two trials in the first quarter of 2019, and by the end of 2018, respectively.

We are also developing nolasiban, an oral oxytocin receptor antagonist, to improve clinical pregnancy and live birth rates in women undergoing in-vitro fertilization, or IVF. We completed randomization of 778 patients in our European Phase 3 clinical trial in women undergoing IVF, or the IMPLANT 2 clinical trial, in 2017 and reported positive topline results for the primary endpoint of ongoing pregnancy 10 weeks post embryo transfer in February 2018. Based on these IMPLANT 2 results, we are seeking feedback from regulatory authorities in Europe and in the United States on any additional future registration requirements. Following consultation with these regulatory authorities, we plan to initiate a Phase 3 clinical development program in the United States in the fourth quarter of 2018. We expect to receive live birth rate data and 28-day neonatal safety from the IMPLANT 2 clinical trial in the fourth quarter of 2018, followed by 6-month infant follow-up in 2019.

In addition, we are developing OBE022, an oral and selective prostaglandin F2α receptor antagonist, for preterm labor in weeks 24 to 34 of pregnancy. Based on results of Phase 1 clinical trials completed in the first quarter of 2017, we initiated a Phase 2a proof-of-concept clinical trial, known as PROLONG, in December 2017. This trial will initially assess OBE022 safety, and subsequently efficacy in delaying childbirth in women at 24 to 34 weeks gestation who are experiencing symptoms of preterm labor and potentially preterm delivery. We expect interim efficacy results in a subset of patients from this trial to be available in the fourth quarter of 2018.

We were founded in November 2012 and our operations to date have included organizing and staffing our company, raising capital, in-licensing rights to OBE2109, nolasiban and OBE022 and conducting nonclinical studies and clinical trials. To date, we have not generated any revenue from product sales as none of our product candidates have been approved for commercialization. We have historically financed our operations exclusively through the sale of equity. To date, we have raised an aggregate of $238.1 million of net proceeds, including $88.6 million of net proceeds from our initial public offering in January 2017 and $56.3 million of net proceeds from our private placement with institutional investors in October 2017, and also acquired license rights on product candidates in 2013 and 2015 from the sale of preferred shares.

We have never been profitable and have incurred significant net losses in each period since our inception. Our net losses were $19.8 million and $15.5 million for the three-month periods ended March 31, 2018, and 2017, respectively. As of March 31, 2018, we had accumulated losses of $157.1 million, out of which $30.6 million were offset with share premium. This reclassification transaction had no impact on total equity. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We used $14.8 million and $10.6 million of cash in operations in the three-month periods ended March 31, 2018, and 2017, respectively, and we anticipate that our expenses will continue to increase significantly in connection with our ongoing activities as we:

- continue to invest in the clinical development of our product candidates and specifically to support our ongoing EDELWEISS, PRIMROSE 1 and 2, IMPLANT 2 and PROLONG clinical trials, and any additional clinical trials, nonclinical studies and pre-commercial activities that we may conduct for product candidates;
- hire additional research and development, commercial and general and administrative personnel;
- maintain, expand and protect our intellectual property portfolio;

- identify and in-license or acquire additional product candidates; and
- continue to incur additional costs associated with operating as a public company.

We will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for and invest in future commercialization of these candidates, if approved. Adequate funding may not be available to us on acceptable terms, or at all.

We have no manufacturing facilities, and all of our manufacturing activities are contracted out to third parties. We currently utilize third-party contract research organizations, or CROs, to carry out our clinical development and trials. Additionally, we are initiating the establishment of an infrastructure to address our potential future pre-commercial and commercial needs.

Strategic Licensing Agreements

OBE2109

In November 2015, we entered into the Kissei license and supply agreement with Kissei Pharmaceutical Co., Ltd., or Kissei. Pursuant to the Kissei license and supply agreement we received an exclusive license to develop, manufacture and commercialize products, or the Product, containing the compounds which is a specified GnRH antagonist and covered by certain licensed patent rights, or the Compound, throughout the world except for specified Asian countries. We arranged to exclusively acquire from Kissei the material necessary to produce OBE2109.

In consideration for the license, we made an initial $10.0 million upfront payment. In addition, we agreed to make aggregate milestone payments of up to $63.0 million upon the achievement of specified developmental milestones, such as the initiation of clinical trials and receipt of regulatory approvals. In connection with the initiation of the Phase 3 clinical program for OBE2109 in uterine fibroids in the second quarter of 2017, a $5.0 million milestone payment was made. With respect to any products we commercialize under the Kissei license and supply agreement, we agreed to make further payments of up to an additional $125.0 million to Kissei upon the achievement of specified commercial milestones.

Pursuant to the Kissei license and supply agreement, we have agreed to exclusively purchase the active pharmaceutical ingredient for OBE2109 from Kissei. During the development stage, we are obligated to pay Kissei a specified supply price. Following the first commercial sale of licensed product, we are obligated to pay Kissei a royalty in the low twenty percent range as a percentage of net sales. This payment includes Kissei's supply of the active pharmaceutical ingredient until the latest of (i) the date that the valid claim of a patent for the Product has expired, (ii) the expiration of our regulatory exclusivity period, or (iii) 15 years from the first commercial sale of such product on a country-by-country and product-by-product basis. During the term, we are restricted from developing, marketing and selling GnRH agonists and GnRH antagonists other than the Compound to the extent allowed by applicable laws.

Nolasiban

In August 2013, we entered into the 2013 license agreement with Ares Trading S.A., an affiliate of Merck Serono, or Merck Serono, pursuant to which we received a worldwide exclusive license to develop, manufacture and commercialize compounds covered by the licensed patent rights, including nolasiban. In consideration for the license, we issued 914,069 Series A preferred shares to Merck Serono at the time of our Series A financing, which had a fair-value of $4.9 million based on an exchange rate of $1.00 for CHF 0.9244 as of the date of the transaction. With respect to any products we commercialize under the 2013 license agreement, we agreed to pay Merck Serono royalties based on a high-single-digit percentage of annual net sales of each product, subject to specified reductions, until the later of (i) the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis, or (ii) ten years from the first commercial sale of such product on a country-by-country and product-by-product basis.

OBE022

In June 2015, we entered into the 2015 license agreement with Merck Serono, which we amended in July 2016, pursuant to which we received a worldwide exclusive license to develop, manufacture and commercialize compounds covered by the licensed patent rights, including OBE022. In consideration for the license, we issued 325,000 Series A preferred shares to Merck Serono in September 2016 upon the initiation of a Phase 1 clinical trial for a licensed product. With respect to any products we commercialize under the 2015 license agreement, we agreed to pay Merck Serono royalties based on a mid-single-digit percentage of annual net sales of each product, subject to specified reductions, until the later of (i) the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or (ii) ten years from the first commercial sale of such product on a country-by-country and product-by-product basis.

Components of Results of Operations

Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the near term.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with our research and development activities and consist mainly of direct research and development costs, which include: costs associated with the use of CROs and consultants hired to assist on our research and development activities; personnel expenses, which include salaries, benefits and share-based compensation expenses for our employees; expenses related to regulatory affairs and intellectual property; manufacturing costs in connection with conducting nonclinical studies and clinical trials; and depreciation expense for assets used in research and development activities. Research and development costs are generally expensed as incurred. However, costs for certain activities, such as manufacturing and nonclinical studies and clinical trials, are generally recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and collaborators.

Our employee, consultant and infrastructure resources are typically utilized across our multiple research and development programs. We track outsourced research and development costs by product candidate or nonclinical program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates.

From inception through March 31, 2018, we have incurred $126.0 million in research and development expenses to advance the development of our product candidates. The following table provides a breakdown of our outsourced research and development expenses that are directly attributable to the specified product candidates for the three-months ended March 31, 2018 and March 31, 2017, respectively.

	For the three-months ended March 31,	
	2018	2017
	(in thousands) (unaudited)	
OBE2109	$ (10,824)	$ (7,672)
Nolasiban	(1,577)	(1,412)
OBE022	(592)	(689)
Total outsourced research and development expenses	$ (12,993)	$ (9,773)

We expect our research and development expense will increase for the foreseeable future as we seek to advance the development of our product candidates through clinical trials and potentially toward regulatory submissions. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates. This is due to the numerous risks and uncertainties associated with developing such product candidates, including:

- the number of clinical sites included in the trials;
- the length of time required to enroll suitable patients;
- the number of patients that ultimately participate in the trials;
- the number of doses patients receive;
- the duration of patient follow-up;
- the results of our clinical trials; and
- regulatory requirements in support of potential approvals.

In addition, the probability of success for any of our product candidates will depend on numerous factors, including competition, manufacturing capability and commercial viability. A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and share-based compensation expense, related to executive, finance, accounting, business development, legal and human resource functions. General and administrative expense also includes facility costs not otherwise included in research and development expenses, legal fees related to corporate matters, fees for accounting and consulting services, and costs of director and officer insurance.

We anticipate that our general and administrative expense will increase in the future to support continued research and development activities. We also anticipate that we will incur increased accounting, audit, legal, regulatory and compliance costs, as well as investor and public relations expenses, associated with operating as a public company.

Finance Result, Net

Finance result, net, consists mainly of interest income and expense derived from our cash and cash equivalents and foreign exchange gains and losses.

Taxation

We are subject to corporate taxation in Switzerland, Ireland and the United States.

In 2015, the Canton of Geneva granted us a ten year tax holiday for all income and capital taxes on a communal and cantonal level commencing in fiscal year 2013 and valid through to 2022, subject to our Swiss domiciliation and compliance with certain reporting provisions. We remain subject to Swiss federal income tax on our profits after tax but have only incurred net losses since our inception. We are entitled under Swiss laws to carry forward any losses incurred for a period of seven years and can offset such losses carried forward against future taxes. As of December 31, 2017, we had tax loss carryforwards totaling $118.0 million. We do not believe it is probable that we will generate sufficient profits to avail ourselves of these tax loss carryforwards.

Our Irish subsidiary had no activity in the three-month periods ended March 31, 2018 and 2017, and our U.S. subsidiary, as a service organization to the group under cost plus arrangement, was the only entity to generate income tax expenses during these periods.

Analysis of Results of Operations

Comparison of the three-months ended March 31, 2018 and March 31, 2017

Operating Expenses

Research and Development Expenses

	For the three-months ended March 31,	
	2018	2017
	(in thousands) (unaudited)	
Research and development expenses by product candidate		
OBE2109	$ (10,824)	$ (7,672)
Nolasiban	(1,577)	(1,412)
OBE022	(592)	(689)
Unallocated expenses		
Staff costs	(2,822)	(2,845)
Other research and development costs	(527)	(439)
Total research and development expenses	$ (16,342)	$ (13,057)

Research and development expenses increased by $3.3 million in the three-months ended March 31, 2018 compared to the three-months ended March 31, 2017 primarily due to the increased costs of $3.2 million resulting from our OBE2109 programs, including increased costs of $2.2 million related to our ongoing PRIMROSE clinical trials.

General and Administrative Expenses

	For the three-months ended March 31,	
	2018	2017
	(in thousands) (unaudited)	
Staff costs	$ (2,271)	$ (1,403)
Professional fees	(906)	(958)
Other general and administrative costs	(472)	(384)
Total general and administrative expenses	$ (3,649)	$ (2,745)

General and administrative expenses increased by $0.9 million in the three-months ended March 31, 2018 compared to the three-months ended March 31, 2017 primarily due to increased staff costs of $0.9 million associated with increased headcount and share-based compensation.

Finance Result, Net

	For the three-months ended March 31,	
	2018	2017
	(in thousands) (unaudited)	
Finance result, net (gain)	$ 155	$ 258

Finance gains in the three-months ended March 31, 2018 and March 31, 2017 primarily consisted of foreign exchange gains.

Liquidity and Capital Resources

Since our inception, we have not generated any revenue and have incurred net losses and negative cash flows from our operations. We have funded our operations primarily through the sale of equity. From inception through March 31, 2018, we have raised an aggregate of $238.1 million of net proceeds from the sale of equity securities. In January 2017, we completed our initial public offering of 6,450,000 common shares at a public offering price of $15.00 per share. We received $88.6 million in net proceeds after deducting $8.2 million of underwriting discounts and commissions and other offering expenses. Additionally, in October 2017, we raised $56.3 million of net proceeds after deducting $3.7 million of placement expenses through the issuance of 7,500,000 shares at a price of $8.00 per share in a private placement with institutional investors.

As of March 31, 2018, we had $95.4 million in cash and cash equivalents.

Our primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We currently have no ongoing material financing commitments, such as lines of credit or guarantees.

We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to program sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

We expect our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2019. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:

- the scope, progress, results and costs of our ongoing and planned nonclinical studies and clinical trials for OBE2109, nolasiban and OBE022;
- the cost and timing of ongoing and planned manufacturing activities including active pharmaceutical ingredient and drug product pharmaceutical development and clinical trial supplies production for OBE2109, nolasiban and OBE022;

- the timing and amount of milestone and royalty payments we are required to make under our license agreements;
- the extent to which we in-license or acquire other product candidates and technologies;
- the number and development requirements of other product candidates that we may pursue;
- the costs, timing and outcome of regulatory review of our product candidates;
- the costs and timing of future commercialization activities, including drug manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
- the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
- our ability to establish strategic collaborations; and
- the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims.

Identifying potential product candidates and conducting nonclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.

Until such time that we can generate substantial product revenue, if ever, we may finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, shareholder ownership interest may be diluted, and the terms of any additional securities may include liquidation or other preferences that adversely affect the rights of shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us.

If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

The following table shows a summary of our cash flows for the three-months ended March 31, 2018 and March 31, 2017:

	For the three-months ended March 31,	
	2018	2017
	(in thousands) (unaudited)	
Cash and cash equivalents at beginning of period	$ 110,841	$ 25,508
Net cash used in operating activities	(14,762)	(10,591)
Net cash used in investing activities	(96)	(9)
Net cash (used in) / from financing activities	(702)	88,985
Effect of exchange rates	154	265
Cash and cash equivalents at end of period	$ 95,435	$ 104,158

Operating Activities

Net cash used in operating activities consists of net loss before tax adjusted for changes in net working capital, that is current assets less current liabilities, and for non-cash items such as depreciation and amortization and the value of share-based services.

During the three-months ended March 31, 2018, cash use from operating activities was $14.8 million, primarily as the result of our net loss before tax of $19.8 million, as adjusted for non-cash items and changes in the net working capital. Non-cash items amounted to $2.3 million and mainly consisted of share-based payments. Changes in the net working capital included primarily a $4.3 million increase in accrued expenses, mainly due to the costs of our PRIMROSE clinical trials and CMC formulation development costs for nolasiban, and a $1.2 million decrease in other payables and current liabilities mainly due to the invoice phasing for our clinical trials with OBE2109.

During the three-months ended March 31, 2017, cash use from operating activities was $10.6 million, primarily as the result of our net loss before tax of $15.5 million, as adjusted for non-cash items and changes in the net working capital. Non-cash items amounted to $2.1 million and mainly consisted of share-based payments. Changes in the net working capital included primarily a $2.5 million increase in accrued expenses, mainly due to the commencement of clinical activities for our PRIMROSE clinical trials and our ongoing EDELWEISS clinical trial.

Investing Activities

During the three-months ended March 31, 2018and the three-months ended March 31, 2017, net cash used in investing activities consisted primarily of investments in leasehold improvements, furniture and fixtures.

Financing Activities

During the three-months ended March 31, 2018, net cash used in financing activities consisted primarily of final payments made in relation with our private placement of October 2017, including mainly a 1% Swiss stamp tax due on the amount of gross proceeds.

During the three-months ended March 31, 2017, net cash from financing activities consisted primarily of net proceeds from the sale of equity securities in our IPO.

Main Contractual Obligations and Commitments

Under our license agreements with Kissei and Merck Serono, we may be required to pay royalties in the future. In addition, pursuant to the Kissei license and supply agreement, we have agreed to make aggregate milestone payments of up to $63.0 million upon the achievement of specified developmental milestones, such as the initiation of clinical trials and receipt of regulatory approvals, out of which $5.0 million were already paid as of March 31, 2018. With respect to any product we commercialize under the Kissei license and supply agreement, we have agreed to make additional aggregate milestone payments of up to $125.0 million to Kissei upon the achievement of specified commercial milestones.

We enter into contracts in the normal course of business with CROs for clinical trials, nonclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

Off-Balance Sheet Arrangements

As of the date of this discussion and analysis, and during the periods presented, we did not have any off-balance sheet arrangements.

Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated interim financial statements, which we have prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board.

The accounting policies used in the preparation and presentation of these consolidated interim financial statements are consistent with those used in the consolidated financial statements for the year ended December 31, 2017, which should be read in conjunction with these consolidated interim financial statements and management's discussion and analysis as they provide an update of previously reported information.

The preparation of our consolidated interim financial statements requires us to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the interim financial statements. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates.

Recent Accounting Pronouncements

The adoption of IFRS standards as issued by the IASB and interpretations issued by the IFRS interpretations committee that are effective for the first time for the financial year beginning on or after January 1, 2018 had no material impact on our financial position.

JOBS Act Exemption

In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended for complying with new or revised accounting standards. Thus, an emerging growth company can

delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

As an emerging growth company, subject to certain conditions, we are relying on certain of exemptions under the JOBS Act, including without limitation, (1) providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (2) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier to occur of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenues of at least $1.07 billion or (c) in which we are deemed to be a "large accelerated filer" under the rules of the U.S. Securities and Exchange Commission, which means the market value of our common shares that is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

Cautionary Statement Regarding Forward-Looking Statements

Forward-looking statements appear in a number of places in this discussion and analysis and include, but are not limited to, statements regarding our intent, belief or current expectations. Many of the forward-looking statements contained in this discussion and analysis can be identified by the use of forward-looking words such as "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "ongoing", "objective", "plan", "potential", "predict", "should", "will" and "would", or the negative of these and similar expressions. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section entitled "Item 3.D—Risk Factors" in the Annual Report on Form 20-F for the year ended December 31, 2017, or the Annual Report, filed with the U.S. Securities and Exchange Commission, or the SEC, pursuant to the U.S. Securities and Exchange Act of 1934, as amended. These risks and uncertainties include factors relating to:

- the success, cost, timing and potential indications of our product candidates' development activities and clinical trials, including our ongoing and future trials of OBE2109, nolasiban and OBE022;
- our ability to obtain and maintain regulatory approval of our product candidates, including OBE2109, nolasiban and OBE022, in any of the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved product;
- the results of ongoing or future clinical trials, including of OBE2109, nolasiban and OBE022;
- our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of any of our product candidates, and the terms on which we are able to raise that additional capital;
- our plans to research, develop and commercialize our product candidates;
- the timing of our regulatory filings for our product candidates;
- the clinical utility of our product candidates;
- the size and growth potential of the markets for our product candidates;
- our commercialization, marketing and manufacturing capabilities and strategy;
- our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others;
- the timing and amount of milestone and royalty payments we are required to make under our license agreements;
- our ability to attract and retain qualified employees and key personnel;
- our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
- the activities of our competitors and the success of competing therapies that are or become available;
- our plans to in-license or acquire additional product candidates;
- how long we will qualify as an emerging growth company or a foreign private issuer;
- our estimates regarding future revenue, expenses and needs for additional financing;
- regulatory developments in the United States and foreign countries; and
- other risks and uncertainties, including those listed in the Annual Report, titled "Item 3.D—Risk Factors."

Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

-Key First Quarter 2018 Clinical Milestones Achieved

- ***Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results expected by the end of Q2:18, and***

- ***Primary endpoint achieved in Phase 3 IMPLANT2 trial of nolasiban in IVF, Live Birth Rate data expected in Q4:18***

Geneva, Switzerland and Boston, MA – May 16, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today reported financial results for the quarter ended March 31, 2018, and provided a business update outlining recent corporate progress and upcoming milestones.

"2018 is off to a very good start for ObsEva, with the first quarter announcement of positive IMPLANT2 phase 3 results for nolasiban in IVF said Ernest Loumaye, co-founder and Chief Executive Officer of ObsEva. *"Along with our GnRH antagonist OBE2109, we now believe that we have two late clinical-stage compounds with the potential to significantly improve the treatment of important medical conditions that impact the lives of millions of women globally".*

Recent Pipeline Highlights

- Positive Phase 3 IMPLANT 2 trial top line results were disclosed in February 2018 for ObsEva's oral oxytocin receptor antagonist nolasiban, given as a single dose, 4 hours prior to a single embryo transfer (ET) and designed to improve clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). The primary endpoint was achieved, with a 10-week ongoing pregnancy rate of 35.6% for nolasiban treated patients vs. 28.5% for placebo treated patients, a 25% relative increase (p= 0.031). In the ET Day 5 subgroup, the relative increase was 32% and the absolute increase was 11.2% in favor of nolasiban (nolasiban 45.9% and placebo 34.7%, p = 0.034). In addition, nolasiban treatment was safe and well tolerated with

no difference in rates of discontinuation from treatment emergent adverse events (TEAE's) nor the incidence of serious adverse events (SAE's) as compared to placebo.

- Patient randomization was completed in the first quarter of 2018 for the EDELWEISS Phase 2b clinical trial of OBE2109, ObsEva's oral GnRH receptor antagonist for the treatment of endometriosis. The trial enrolled nearly 330 patients combined in Europe and the U.S., and is comparing 4 different doses of OBE2109 to placebo, with the goal of identifying dosages that can alleviate pain symptoms utilizing either partial or full estrogen suppression to offer potential alternatives both with and without hormonal add back therapy (ABT).

- Patient enrollment continued in the PRIMROSE 1 and PRIMROSE 2 Phase 3 clinical trials of OBE2109 for the treatment of uterine fibroids, with a target enrollment of approximately 1,000 women in total (US and Europe). These trials are designed to reduce heavy menstrual bleeding (HMB) associated with uterine fibroids, with efficacy and safety of 2 doses being studied, one with ABT and one without ABT.

- First patients were enrolled in the PROLONG Phase 2a clinical trial of OBE022, ObsEva's oral prostaglandin F2 alpha receptor antagonist for the treatment of pre-term labor in pregnant women between 24 and 34 weeks of gestation.

Upcoming Milestones

ObsEva expects to achieve the following clinical and regulatory milestones during 2018:

- 12-week results from the Phase 2b EDELWEISS clinical trial of OBE2109 for the treatment of endometriosis, by the end of Q2:18 and readout of 24-week treatment data, including bone mineral density measurement in Q4:18. End-of-phase 2 meeting with regulatory authorities to discuss the design of the phase 3 program for that indication is expected by the end of 2018.

- Given current trends, completion of patient enrollment in the Phase 3 PRIMROSE 2 trial of OBE2109 for the treatment of uterine fibroids continues to be targeted for the end of 2018, while PRIMROSE 1 enrollment completion is anticipated in Q1:19.

- Results of live birth rate and 28-day neonatal safety from the Phase 3 IMPLANT2 clinical trial of nolasiban in IVF in Q4:18. Post consultation with regulatory authorities, initiation of a US Phase 3 clinical development program is planned for Q4:18.

- Safety, tolerability and pharmacokinetics in pregnant women, and interim efficacy from the Phase 2a PROLONG clinical trial of OBE022 in pre-term labor in Q4:18.

First Quarter 2018 Financial Results

Net loss for the first quarter of 2018 was $19.8 million, or ($0.54) per basic and diluted share, vs. $15.5 million or ($0.58) per basic and diluted share for the first quarter of 2017. Research and development expenses were $16.3 million and general and administrative expenses were $3.6 million for the quarter ended March 31, 2018, vs. $13.1 million and $2.7 million, respectively, for the quarter ended March 31, 2017. Our first quarter 2018 net loss included non-cash expenses of $2.4 million for share-based compensation, vs. $2.3 million in the first quarter of 2017.

As of March 31, 2018, ObsEva had cash and cash equivalents of $95.4 million.

Conference Call Information

ObsEva will host a conference call and audio webcast today at 8:00 a.m. Eastern Time, 2 p.m. Central European Time, to provide a business update and discuss first quarter 2018 financial results. To participate in the conference call, please dial 844-419-1772 (U.S.) or (213) 660-0921 (international) and refer to conference ID 5663506. The webcast can be accessed under the “Investors” section of ObsEva’s website www.obseva.com

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates and the timing of enrollment in and data from clinical trials. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2017, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s

website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
212-223-4017

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
857-972-9347 office
781-366-5726 mobile

Consolidated Statements of Comprehensive Loss

(in USD '000, except per share data)	For the three-months ended March 31, 2018	2017
	unaudited	
Operating income other than revenue	**5**	**6**
OPERATING EXPENSES		
Research and development expenses	(16,342)	(13,057)
General and administrative expenses	(3,649)	(2,745)
Total operating expenses	**(19,991)**	**(15,802)**
OPERATING LOSS	**(19,986)**	**(15,796)**
Finance income	155	258
Finance expense	—	—
NET LOSS BEFORE TAX	**(19,831)**	**(15,538)**
Income tax benefit	25	—
NET LOSS FOR THE PERIOD	**(19,806)**	**(15,538)**
Net loss per share		
Basic	(0.54)	(0.58)
Diluted	(0.54)	(0.58)
Weighted Average Number of Shares Outstanding	36,389,578	26,623,553

Consolidated Balance Sheets

(in USD '000)	March 31, 2018	December 31, 2017
	unaudited	*audited*
ASSETS		
Current assets		
Cash and cash equivalents	95,435	110,841
Other receivables	791	783
Prepaid expenses	1,786	1,490
Total current assets	**98,012**	**113,114**
Non-current assets		
Furniture, fixtures and equipment	310	323
Intangible assets	21,608	21,608
Other long-term assets	192	190
Total non-current assets	**22,110**	**22,121**
Total assets	**120,122**	**135,235**
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Current tax liability	27	51
Other payables and current liabilities	1,613	2,865
Accrued expenses	10,106	6,514
Total current liabilities	**11,746**	**9,430**
Non-current liabilities		
Post-employment obligations	3,063	3,099
Other long-term liabilities	53	55
Total non-current liabilities	**3,116**	**3,154**
Shareholders' equity		
Share capital	2,871	2,864
Share premium	220,141	219,335
Reserves	8,721	7,119
Accumulated losses	(126,473)	(106,667)
Total shareholders' equity	**105,260**	**122,651**
Total liabilities and shareholders' equity	**120,122**	**135,235**

###